Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04018313




Registration number
NCT04018313
Ethics application status
Date submitted
9/07/2019
Date registered
12/07/2019
Date last updated
11/05/2023

Titles & IDs
Public title
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Scientific title
A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Secondary ID [1] 0 0
CT-P39 1.1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - CT-P39
Treatment: Other - EU-approved Xolair
Treatment: Other - CT-P39
Treatment: Other - EU-approved Xolair
Treatment: Other - US-licensed Xolair

Experimental: CT-P39 (Part 1) - 150 mg/mL, Solution for injection in PFS

Active comparator: EU-approved Xolair (Part 1) - 150 mg/mL, Solution for injection in PFS

Experimental: CT-P39 (Part 2) - 150 mg/mL, Solution for injection in PFS

Active comparator: EU-approved Xolair (Part 2) - 150 mg/mL, Solution for injection in PFS

Active comparator: US-licensed Xolair (Part 2) - 150 mg/mL, Solution for injection in PFS


Treatment: Other: CT-P39
150 mg/mL, Solution for injection in PFS

Treatment: Other: EU-approved Xolair
150 mg/mL, Solution for injection in PFS

Treatment: Other: CT-P39
150 mg/mL, Solution for injection in PFS

Treatment: Other: EU-approved Xolair
150 mg/mL, Solution for injection in PFS

Treatment: Other: US-licensed Xolair
150 mg/mL, Solution for injection in PFS
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pharmacokinetic Outcome Measures [AUC0-inf] for Part 2
Timepoint [1] 0 0
up to day 127
Primary outcome [2] 0 0
Pharmacokinetic Outcome Measures [AUC0-last] for Part 2
Timepoint [2] 0 0
up to day 127
Primary outcome [3] 0 0
Pharmacokinetic Outcome Measures [Cmax] for Part 2
Timepoint [3] 0 0
up to day 127
Secondary outcome [1] 0 0
Pharmacokinetic Outcome Measures [Tmax] for Part 1& Part 2
Timepoint [1] 0 0
up to day 127
Secondary outcome [2] 0 0
Pharmacokinetic Outcome Measures [t1/2] for Part 1& Part 2
Timepoint [2] 0 0
up to day 127
Secondary outcome [3] 0 0
Pharmacodynamics Outcome Measures [Cmin of Free IgE] for Part 1 & Part 2
Timepoint [3] 0 0
up to day 127
Secondary outcome [4] 0 0
Pharmacodynamic Outcome Measures [Tmin of Free IgE] for Part 1 & Part 2
Timepoint [4] 0 0
Up to day 127
Secondary outcome [5] 0 0
Pharmacodynamic Outcome Measures [Cmax of Total IgE] for Part 1 & Part 2
Timepoint [5] 0 0
up to day 127
Secondary outcome [6] 0 0
Pharmacodynamic Outcome Measures [Tmax of Total IgE] for Part 1 & Part 2
Timepoint [6] 0 0
up to day 127

Eligibility
Key inclusion criteria
* Healthy subject (male or female) between the ages of 18 and 55 years.
* Subject with a body weight of > 40 kg and = 90 kg and a BMI between 18.0 kg/m2 and 32.0 kg/m2(both inclusive).
* Subject with a total IgE level of = 100 IU/mL.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Subject has a medical history and/or current presence of disease including one or more of the allergic reaction.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/05/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/04/2021
Sample size
Target
Accrual to date
Final
176
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
Phase 1 unit - Herston
Recruitment hospital [2] 0 0
Phase 1 unit - Adelaide
Recruitment postcode(s) [1] 0 0
4006 - Herston
Recruitment postcode(s) [2] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Celltrion
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Trial website
https://clinicaltrials.gov/study/NCT04018313
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
SungHyun Kim
Address 0 0
Celltrion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04018313